Cargando…

Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens

BACKGROUND: Gemcitabine plus cisplatin (GP) is a novel regimen of induction chemotherapy (IC) for treating locoregional advanced nasopharyngeal cancer (NPC). This retrospective study aimed to compare the efficacy of GP and TP (paclitaxel plus cisplatin) regimens in tumor volume reduction after IC. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Li, Liao, Wenjun, Xu, Peng, Li, Baisen, Wen, Hao, Zhang, Shichuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237045/ https://www.ncbi.nlm.nih.gov/pubmed/30406770 http://dx.doi.org/10.12659/MSM.909736

Ejemplares similares

The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma
por: Li, Xiao‐Min, et al.
Publicado: (2022)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

Comparison of Gemcitabine Plus Cisplatin vs. Docetaxel Plus Fluorouracil Plus Cisplatin Palliative Chemotherapy for Metastatic Nasopharyngeal Carcinoma
por: Sun, Xue-Song, et al.
Publicado: (2020)

Is Gemcitabine and Cisplatin Induction Chemotherapy Superior in Locoregionally Advanced Nasopharyngeal Carcinoma?
por: Zheng, Wei, et al.
Publicado: (2015)

Gemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma
por: Li, Qiongxuan, et al.
Publicado: (2018)

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
por: Yang, Jiangping, et al.
Publicado: (2020)

Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma
por: Li, Yin, et al.
Publicado: (2015)

Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2019)

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience
por: Abdelrahim, Maen, et al.
Publicado: (2022)

Concurrent chemotherapy using taxane plus cisplatin versus cisplatin alone in high-risk nasopharyngeal carcinoma patients with suboptimal response to induction chemotherapy
por: Zhang, Ya-Ni, et al.
Publicado: (2023)

Comparison Efficacy and Safety of Gemcitabine plus Cisplatin and 5-Fluorouracil plus Cisplatin for Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis and Systematic Review
por: Yan, Le, et al.
Publicado: (2022)

Endostar Combined with Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Nasopharyngeal Carcinoma: an Update
por: Jin, Ting, et al.
Publicado: (2018)

Durable response for ampullary and duodenal adenocarcinoma with a nab‐paclitaxel plus gemcitabine ± cisplatin combination
por: Cen, Putao, et al.
Publicado: (2019)

Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2018)

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2016)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
por: Zhang, Mengping, et al.
Publicado: (2020)

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial
por: Wang, Yan, et al.
Publicado: (2022)

Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
por: Jung, Kwangrok, et al.
Publicado: (2022)

Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder
por: Kim, Hongsik, et al.
Publicado: (2023)

A comparison of neoadjuvant chemotherapy with gemcitabine versus docetaxel plus cisplatin in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis
por: Liu, Tongxin, et al.
Publicado: (2018)

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy
por: Han, K S, et al.
Publicado: (2008)

Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study
por: Hong, Shaodong, et al.
Publicado: (2021)

Clinical value of docetaxel plus cisplatin (TP) induction chemotherapy followed by TP concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma
por: Tao, Hao-Yun, et al.
Publicado: (2021)

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma()()()()
por: Jin, Ting, et al.
Publicado: (2019)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Chemotherapy with gemcitabine plus cisplatin in patients with advanced thymic squamous cell carcinoma: Evaluation of efficacy and toxicity
por: Luo, Yang, et al.
Publicado: (2015)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

Magnetic Resonance Imaging Volumetry of Primary Nasopharyngeal Cancer in Patients Treated with Induction Gemcitabine and Cisplatin Followed by Concurrent Cisplatin and Volumetric Modulated Arc Therapy
por: Giambattista, Joshua, et al.
Publicado: (2018)

Comparative Study Between Two Treatment Regimens of Cisplatin-5-Fluorouracil and Gemcitabine-Cisplatin in Gallbladder Cancer Patients
por: Ali, Daud, et al.
Publicado: (2017)

Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
por: Huang, Yan, et al.
Publicado: (2016)

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy
por: Lv, Jia‐Wei, et al.
Publicado: (2018)

Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review
por: He, Wan, et al.
Publicado: (2016)

Study of Gemcitabine Plus Nab-Paclitaxel-Based Chemotherapy Regimen as First-Line Treatment in Metastatic Pancreatic Carcinoma
por: Domadia, Kshitij, et al.
Publicado: (2021)

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
por: Ioka, Tatsuya, et al.
Publicado: (2022)

Safety of adjuvant gemcitabine plus cisplatin chemotherapy in a patient with bilateral ureteral cancer undergoing hemodialysis
por: Goto, Yumiko, et al.
Publicado: (2021)

Probiotics enhances anti‐tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer
por: Miyake, Makito, et al.
Publicado: (2022)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients
por: Li, Ying, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f575tvkc4lhstk4aerpqnhaurr